| PART I EXPRESSION OF SALL4IN CHILDHOOD ACUTELEUKEMIA AND ITS CLINICAL SIGNIFICANCEObjective To investigate the expression level of SALL4in childhoodleukemia and analyze its potential clinical significance.Methods Real-time PCR and immunocytochemical staining wereapplied to examine the mRNA and protein expression level of SALL4inBMMSC of50cases of newly diagnosed acute leukemia (including24cases of B-ALL,4cases of T-ALL,22cases of AML) and15cases ofidiopathic thrombocytopenic purpura(ITP) controls. The level of SALL4mRNA in newly diagnosed phase and complete remission phase wasdetected in5cases of acute leukemia. Then relationship between mRNAlevel of SALL4and clinical indicators was analyzed.Results1.The mRNA expression of SALL4in newly diagnosed Pre-B-ALL[13.89(1.00-63.15)] and AML [11.12(2.31-56.59)] was higher thancontrols [1.00(0.29-1.71)](P<0.01). However, no significant difference between newly diagnosed T-ALL [1.48(0.87-4.81)] and control(P>0.05)was observed.2.The positive rate of SALL4protein in newly diagnosed Pre-B-ALL,AML and T-ALL was83.33%(20/24),86.36%(19/22),0(0/4), respectively.The expressions of SALL4protein in15controls were all negative.Compared with control group, the expression of SALL4protein inPre-B-ALL and AML was higher (P <0.01). However, the expression ofSALL4protein showed no significant difference(P>0.05) between T-ALLand control. These results were in accordance with real-time PCR.3.The mRNA levels of SALL4significantly decreased in completeremission phase [0.98(0.22-1.09)] than those in acute phase[28.64(11.20-87.46)] in5cases of acute leukemia(P<0.01).4.High level of SALL4was positively correlated with high whiteblood cell(WBC) counts, high risk classification and high minimal residualdisease(MRD) in the end of induction chemotherapy period(r=0.424,r=0.403, r=0.393, P<0.05). However it was not associated with age, gender,hepatomegaly, splenomegaly and lymphadenectasis(P>0.05).Conclusion1.The expression of SALL4is high in newly diagnosed Pre-B-ALLand AML, but significantly decreased in complete remission phase. SALL4is implied to play an important role to promote pediatric Pre-B-ALL andAML. 2.The expression of SALL4is positive in Pre-B-ALL and AML, butnegative in T-ALL. Compared with Pre-B-ALL and AML, the pathogenesisof T-ALL is different.3.The high level of SALL4is positively correlated with high WBC,high risk classification and high MRD in the end of inductionchemotherapy period but is not associated with age, gender, hepatomegaly,splenomegaly and lymphadenectasisand. SALL4expression level promisesa new target for monitoring therapy and judging prognosis. PART II EFFECT OF APIGENIN ON PROLIFERATIONAND APOPTOSIS OF U937CELLS AS WELL AS ONEXPRESSION OF SALL4Objective To investigate the effect of apigenin on proliferation andapoptosis of U937cells as well as on expression of SALL4.Methods U937cells were cultured with different concentrations ofapigenin (0,20,40,60μmol/L), and cell morphology was observed under aninverted microscope; Proliferation activity was evaluated by CCK-8. Thecell cycle and apoptosis was determined by flow cytometry. The mRNAexpression levels of SALL4, C-MYC and CCND1were detected byreal-time PCR; The protein expression levels of SALL4, BCL-2andCaspase-3were analyzed by western blot. Results Compared with control group, treatment groups showed morecell debris; Cell proliferation was inhibited in a time-and does-dependentmanner(P<0.05); Cell ratio in G2/M and cell apotosis increased(P<0.05).After cultured with different concentration of apigenin for36h, the mRNAexpression levels of SALL4, C-MYC and CCND1were down-regulated;The protein expression levels of SALL4and BCL-2decreased whileCaspase-3increased.Conclusion Apigenin may inhibit the proliferation and induceapoptosis of U937cells as well as arrest U937cells in G2/M period. Themechanism is possibly related with down-regulating transcription factorSALL4and regulating apoptosis-related protein BCL-2and Caspase-3, aswell as inhibiting oncogene C-MYC and CCND1. |
PDF Full Text Request